Full-Time

Medical Director

Drug Safety

Posted on 6/6/2025

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Compensation Overview

$250k - $315k/yr

Senior

Remote in USA

Remote

This is a U.S.-based remote role that will generally require three visits per year, or as-needed visits to our San Francisco Office.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Medical Degree
  • Requires at least five years of drug safety and pharmacovigilance experience (clinical trials safety experience in the biotechnology, pharmaceutical, drug safety contract service organization (CSO)) with at least two years of oversight management experience (line management or CSO management)
  • Extensive experience with all aspects safety signal evaluation, including review and analysis of data, collaboration with cross-functional team members and senior management, authoring of required regulatory correspondence, and safety label updates
  • Experience in both clinical development and post-marketing safety
  • Experience with Regulatory submissions for NDAs, EU MAAs, and other countries’ Regulatory reviews
  • Demonstrated ability to successfully manage a drug safety team or drug safety CRO for a clinical development program with responsibilities for expedited reporting, on-time DSUR preparation
  • Experience in drug safety audits and agency inspections
  • Intimate knowledge of GCP and strong working knowledge of FDA, Good Clinical Practices, and ICH regulations and guidelines
  • Proven ability to collaborate successfully with clinical trial teams, including data management, clinical sciences, medical monitors, clinical operations, biostatistics, regulatory, medical writing, and QA
  • Experience in managing all clinical safety aspects of product quality defect investigations and assessments
  • Management of compliance deviations and formulations of CAPAs
  • Familiar with clinical trial safety database use and CIOMS II and DSUR reporting generation (Argus, ArisG, or VeevaSafety) and Microsoft Office Suite required (Word, Excel, PowerPoint, Project, Outlook)
  • Must be able and willing to travel periodically for face-to-face engagements with regulatory authorities, and occasional on-site meetings (if based remotely)
Responsibilities
  • Support the clinical development team in the review of key documents, including protocol and ICFs
  • Manage the drug safety contract service organizations (CROs) for clinical programs to ensure compliance with expedited reporting, manage on-time and scientifically sound DSUR preparation, and ensure the drug safety functions of the CROs meet corporate goals and key performance indicators
  • Assist in the medical review of adverse event reports; manage the preparation and submission of drug safety expedited reporting in compliance with regulations, when necessary
  • Develop and prepare assessments of safety data, safety signals, and benefit/risk for internal senior management, as well as external partners or regulatory authorities
  • Assist in the authoring of aggregate reports

BridgeBio Pharma focuses on developing medicines for genetic diseases, targeting conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources, which enhances efficiency and speeds up drug development. By leveraging advancements in genome sequencing and molecular biology, BridgeBio aims to create effective treatments and has a diverse pipeline of over 15 drug programs for 20 different genetic diseases. Their goal is to bring therapies to market faster while fostering a culture of independent thinking and transparency.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $300M royalty monetization strengthens BridgeBio's financial position.
  • Approval of Beyonttra in Japan marks a significant milestone for BridgeBio.
  • BridgeBio's robust pipeline targets over 20 genetic diseases, enhancing market potential.

What critics are saying

  • Increased competition from Alnylam's Amvuttra may impact BridgeBio's market share.
  • Reliance on royalty monetization deals could indicate potential cash flow challenges.
  • Decentralized model may lead to challenges in strategic direction and resource allocation.

What makes BridgeBio unique

  • BridgeBio employs a unique decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows BridgeBio to target well-understood genetic causes.
  • BridgeBio leverages genome sequencing and molecular biology for innovative therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↑ 3%

2 year growth

↑ 0%
Wallstreet Online
Jun 30th, 2025
BridgeBio Raises $300M via Royalty Monetization

BridgeBio has secured a $300 million upfront payment by monetizing 60% of its European royalties on the first $500 million of annual BEYONTTRA net sales, with a cap of 1.45x on total payments. This deal with HealthCare Royalty and Blue Owl Capital strengthens BridgeBio's balance sheet and supports the launch of Attruby and its late-stage pipeline. Acoramidis, approved as Attruby in the U.S. and BEYONTTRA in Europe, has shown significant benefits in the ATTRibute-CM study.

Bitcoin Ethereum News
Jun 20th, 2025
Parataxis Korea's $18.5M BTC Strategy

Parataxis Holdings is launching a BTC treasury company in South Korea through a reverse merger with Bridge Biotherapeutics, valued at â‚©25M ($18.5M). The new entity, Parataxis Korea, aims to emulate the BTC strategies of Strategy in the US and Metaplanet in Japan. Bridge Biotherapeutics, previously distressed, saw its stock rise after the BTC strategy shift. Parataxis Capital, affiliated with Parataxis Holdings, is a Tier-4 investment fund with a focus on crypto projects.

Stock Titan
May 12th, 2025
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the Heart Failure 2025 conference in Belgrade, Serbia from May 17-20, 2025.

TradingView
May 12th, 2025
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to present clinical outcomes, Quality of Life measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM study at the Annual Congress of the Heart Failure Association of the ESC.

BioSpace
Mar 29th, 2025
Beyonttra(Tm) (Acoramidis), The First Near-Complete Ttr Stabilizer (>=90%), Approved In Japan To Treat Attr-Cm

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in JapanPALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature.1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan.“There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide

INACTIVE